Cgm Dexcom denied for failing step therapy by Aetna?

Aetna's specific coverage criteria for cgm dexcom are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denied Your Dexcom CGM Under Step Therapy

A step-therapy denial means Aetna's coverage policy requires that you first try one or more alternative glucose-monitoring approaches — typically a traditional blood glucose meter (BGM) with a specified testing frequency, or a lower-cost CGM on the formulary — before Dexcom CGM will be authorized. Aetna uses step-therapy requirements to manage costs by ensuring lower-cost monitoring options have been tried first.

This denial is appealable under two circumstances: (1) you already tried and failed the required step-therapy alternative, or (2) the alternative is clinically inappropriate for you and step therapy should be waived.

## Federal and State Protections

• Step-therapy exception laws: Many states have enacted step-therapy exception statutes that require plans to grant exceptions when a required alternative has failed, is contraindicated, or would cause harm. Check whether your state has such a law, as it may apply to your plan.
• Internal appeal (ACA §2719 / ERISA §503): File within the deadline on your denial notice. Aetna must decide within 30 days (standard) or 72 hours (urgent/expedited).
• External review: After a final internal denial, you have the right to independent external review — generally within approximately four months. The IRO decision is binding.
• Expedited review: Available if your condition is urgent.

## Documentation to Gather

1. Trial-and-failure records: If you tried the required step-therapy alternative, document dates of use, the specific clinical inadequacy (e.g., hypoglycemia unawareness not addressed by fingerstick, nocturnal lows not detected), and your prescriber's assessment of why it failed. 2. Clinical inappropriateness letter: If the required alternative was never tried because it is clinically inappropriate for you, your prescriber must document the specific clinical reason — referencing your chart findings, not generic statements. 3. Prescriber medical-necessity letter: Explaining why Dexcom CGM specifically is medically necessary and what clinical goals it achieves that the required alternative cannot. 4. Diagnosis and treatment records: Current chart notes, medication list, ICD codes. 5. Applicable guideline reference: Your prescriber should reference the relevant professional society (e.g., American Diabetes Association) supporting CGM in your clinical profile.

## Criteria-Mapping Structure

Obtain Aetna's step-therapy policy for CGM. Identify the exact alternative(s) required and the criteria for a step-therapy exception. Map your documentation directly to those criteria: prior alternative used (dates and duration), clinical outcome, and reason for failure or clinical inappropriateness. This structured response is far more effective than a narrative letter alone.

Step-therapy appeals with documented trial-and-failure or clinical-inappropriateness rationale succeed at a meaningful rate, particularly in states with step-therapy exception statutes.